Mechanisms of interleukin-10-mediated immune suppression

被引:326
作者
Akdis, CA [1 ]
Blaser, K [1 ]
机构
[1] Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland
关键词
D O I
10.1046/j.1365-2567.2001.01235.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Specific immune suppression and induction of anergy are essential processes in the regulation and circumvention of immune defence. Interleukin-10 (IL-10), a suppressor cytokine of T-cell proliferative and cytokine responses, plays a key regulatory role in tolerizing exogenous antigens during specific immunotherapy (SIT) of allergy and natural exposure to antigens. Specific T-cell tolerance is directed against the T-cell epitopes of an antigen and characterized by suppressed proliferative and T helper type 1 (Th1) and type 2 (Th2) cytokine responses. IL-10 elicits tolerance in T cells by selective inhibition of the CD28 co-stimulatory pathway and thereby controls suppression and development of antigen-specific immunity. IL-10 only inhibits T cells stimulated by low numbers of triggered T-cell receptors and which therefore depend on CD28 co-stimulation. T cells receiving a strong signal from the T-cell receptor alone, and thus not requiring CD28 co-stimulation, are not affected by IL-10. IL-10 inhibits CD28 tyrosine phosphorylation, the initial step of the CD28 signalling pathway, and consequently the phosphatidylinositol 3-kinase p85 binding to CD28. Together these results demonstrate that IL-10-induced selective inhibition of the CD28 co-stimulatory pathway acts as a decisive mechanism in determining whether a T cell will contribute to an immune response or become anergic.
引用
收藏
页码:131 / 136
页数:6
相关论文
共 68 条
[1]   Regulation of specific immune responses by chemical and structural modifications of allergens [J].
Akdis, CA ;
Blaser, K .
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2000, 121 (04) :261-269
[2]  
Akdis CA, 2000, FASEB J, V14, P1666
[3]  
Akdis CA, 1998, EUR J IMMUNOL, V28, P914, DOI 10.1002/(SICI)1521-4141(199803)28:03<914::AID-IMMU914>3.0.CO
[4]  
2-C
[5]   IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy [J].
Akdis, CA ;
Blaser, K .
FASEB JOURNAL, 1999, 13 (06) :603-609
[6]   Epitope-specific T cell tolerance to phospholipase A(2) in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro [J].
Akdis, CA ;
Akdis, M ;
Blesken, T ;
Wymann, D ;
Alkan, SS ;
Muller, U ;
Blaser, K .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (07) :1676-1683
[7]   Mechanisms of allergen-specific immunotherapy [J].
Akdis, CA ;
Blaser, K .
ALLERGY, 2000, 55 (06) :522-530
[8]   Glucocorticoids inhibit human antigen-specific and enhance total IgE and IgG4 production due to differential effects on T and B cells in vitro [J].
Akdis, CA ;
Blesken, T ;
Akdis, M ;
Alkan, SS ;
Heusser, CH ;
Blaser, K .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (09) :2351-2357
[9]   Induction and differential regulation of bee venom phospholipase A(2)-specific human IgE and IgG(4) antibodies in vitro requires allergen-specific and nonspecific activation of T and B cells [J].
Akdis, CA ;
Blesken, T ;
Akdis, M ;
Alkan, SS ;
Wuthrich, B ;
Heusser, CH ;
Blaser, K .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1997, 99 (03) :345-353
[10]   HIGH-LEVELS OF INTERLEUKIN-10 PRODUCTION IN-VIVO ARE ASSOCIATED WITH TOLERANCE IN SCID PATIENTS TRANSPLANTED WITH HLA MISMATCHED HEMATOPOIETIC STEM-CELLS [J].
BACCHETTA, R ;
BIGLER, M ;
TOURAINE, JL ;
PARKMAN, R ;
TOVO, PA ;
ABRAMS, J ;
MALEFYT, RD ;
DEVRIES, JE ;
RONCAROLO, MG .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (02) :493-502